Navigation Links
Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
Date:11/5/2012

SUNNYVALE, Calif., Nov. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal 2013 first quarter ended September 30, 2012.

Financial Results for First Quarter Ended September 30, 2012 The GAAP (Generally Accepted Accounting Principles) net income for the fiscal quarter ended September 30, 2012 was $75.6 million, or $1.09 and $1.02 per basic and diluted earnings per share, respectively. This compares with a GAAP net loss of $14.5 million, or $0.21 loss per basic and diluted share for the fiscal quarter ended September 30, 2011.

The non-GAAP net income reported for the fiscal quarter ended September 30, 2012 was $78.8 million, or $1.14 and $1.07 income per basic and diluted earnings per share, respectively. This compares with a non-GAAP net loss of $12.4 million, or $0.18 basic and diluted loss per share, for the fiscal quarter ended September 30, 2011. See "Use of Non-GAAP Financial Measures" below for a description of our Non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

Revenue for the fiscal quarter ended September 30, 2012 was $102.7 million, compared to $37,000 for the fiscal quarter ended September 30, 2011, an increase of approximately $102.7 million. Revenue for the fiscal quarter ended September 30, 2012 consisted primarily of $100 million of license and milestone revenue due to the Company's achievement of two clinical milestones in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. ("Janssen").

At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million, which compares with $203.6 million at June 30, 2012. Total operating expenses excluding share based compensation during the q
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2012 Results
2. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
3. Global Laparotomy Sponge Market 2011-2015: MarketResearchReports.Biz
4. Global Mobile Health Application Market 2011-2015 : MarketResearchReports.Biz
5. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
6. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
7. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
8. InspireMD Reports 2012 Fiscal Year Results
9. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
10. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
11. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:1/22/2015)... Jan. 22, 2015   GenoSpace , a precision medicine software ... enable the broad use of genomic, imaging and other biomedical ... of Michelle Munson , CEO of Aspera, an IBM ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We are ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2
... Imaging Diagnostic Systems, Inc., (OTC Bulletin ... will exhibit the CT Laser Mammography (CTLM(R)) system at the ... United Arab Emirates (UAE). The company will demonstrate the ... the UAE and intends to secure prospective sales of the ...
... Jan. 27 As farmers,look to get more out ... MON ) is exploring unique ways to discover ... collaboration with GrassRoots,Biotechnology Inc. is expected to do just ... portfolio for its farmer customer. , ...
... Jan. 27 InNexus Biotechnology Inc. (OTC Bulletin Board: ... that it has completed a second private placement on ... that was completed 12 December 2008.The private placement, totaled ... will be convertible into common shares of InNexus at ...
Cached Biology Technology:Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference 2New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers 2New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers 3New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers 4InNexus Completes Previously Announced Private Placement 2
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch in December ... people to eliminate the pain of trying to remember their ... own biometrics fused to their smartphones. To assist people who ... , the company that created 1U and focuses on redefining ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... San Diego have discovered that an important class of stem ... from an individual,s own cells, could face immune rejection problems ... In today,s advance online issue of the journal Nature ... system rejection of cells derived from autologous iPSCs that can ...
... is Not Boring!" asserts the introduction to a recent ... December 2010). On the contrary, the ways in which ... building blocks of macromolecules are crucial for life. And ... single-celled to multicellular organisms. This gives special importance to ...
... a slide that has a photo of a cornfield and ... studies photosynthesis at Washington University in St. Louis. "When I ... more efficient. Invariably the audience votes overwhelmingly in favor of ... its surprising answer (below) is the point of departure for ...
Cached Biology News:Study finds therapies using induced pluripotent stem cells could encounter immune rejection problems 2Turning plants into power houses 2Turning plants into power houses 3Turning plants into power houses 4Turning plants into power houses 5Turning plants into power houses 6
...
...
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
Biology Products: